HAVCR2 and neoplasm: The first by Woroniecka and colleagues evaluated TIM-3 expression on CD8+ T cells from healthy donor PBMCs, glioblastoma patient PBMCs, and tumor-infiltrating lymphocytes (TILs) [101].